Burkitt lymphoma is associated with MYC, the gene recorded in this packet's known genes field. MYC appears in this packet's known_genes_with_validity list; however, no formal ClinGen gene validity classification (such as DEFINITIVE or STRONG) is provided for MYC in the available dataset. No additional causative genes are recorded in the packet beyond MYC. No inheritance pattern is specified in this packet, consistent with Burkitt lymphoma's characterization as a somatic malignancy. No ClinVar pathogenic variant data are recorded for this condition in the available dataset.

No structured clinical diagnostic criteria are recorded in this packet's available fields. Diagnostic information beyond the gene association with MYC and the MONDO anatomic subtype classifications is not enumerated in the accessible dataset. Disease subtypes documented in this dataset — small intestinal Burkitt lymphoma and colon Burkitt lymphoma — indicate site-based diagnostic classification within the broader category. No molecular diagnostic markers beyond MYC are listed in the packet.

This packet records two FDA-approved treatments with ACTIVE market status for Burkitt lymphoma: cyclophosphamide (NDA approval 2023-06-27) and FRINDOVYX, a branded formulation of cyclophosphamide (NDA approval 2023-06-07). No foundational therapies are listed in the packet's foundational_therapies field. Ten clinical trials related to Burkitt lymphoma are recorded in ClinicalTrials.gov data within this packet. Active investigations include a study of zilovertamab vedotin in pediatric and young adult participants with hematologic malignancies (NCT06395103, recruiting), a study of CAR T-cell therapy in B-cell cancers (NCT04464200, active not recruiting), and a study of pomalidomide and dose-adjusted EPOCH regimens for HIV-associated lymphomas (NCT05389423, recruiting). No additional approved agents are recorded beyond the two cyclophosphamide entries in this packet.

No structured natural history or prognosis data are present in this packet's natural history field. Disease course and outcome information for Burkitt lymphoma is not available from the accessible fields in this dataset. Prevalence data are listed as unknown in this packet's prevalence field. No natural history field data were populated in the available knowledge packet.

Ten clinical trials related to Burkitt lymphoma are documented in ClinicalTrials.gov data within this packet. Investigations span hematologic malignancy settings and include studies of novel agents such as zilovertamab vedotin, CAR T-cell approaches, and combination chemotherapy regimens. MYC is the documented associated gene for this condition in this packet. ClinicalTrials.gov is the authoritative source for current enrollment status and eligibility criteria for ongoing research in Burkitt lymphoma.